Big Pharma Dumps Big Money Into Fight Against Prescription Drug Measure

Save ArticleSave Article

Failed to save article

Please try again

A proposed ballot initiative would limit what California can pay for prescription drugs purchased by the state. (Philippe Hugue/AFP/Getty Images)

Pharmaceutical companies continue to pour cash into their campaign to defeat a California ballot measure that would limit prescription drug prices, a new campaign finance analysis shows.

An analysis by MapLight, a nonpartisan organization that tracks money in politics, says the pharmaceutical industry has poured $49 million into the effort to defeat a ballot measure that would limit how much the state can pay for prescription drugs it purchases for a range of people, from those in prisons to Medi-Cal enrollees.

MapLight says that the drug measure's sole financial backer, the AIDS Healthcare Foundation, has put about $4.4 million into the campaign so far.

The companies opposing the initiative, the California Drug Price Relief Act, have banded together in a campaign committee called Californians Against the Misleading Rx Measure.

MapLight notes that 27 of the 30 companies in the committee are based out of state, a fact borne out by California secretary of state records. The table below compiles the secretary of state's campaign finance data for the 30 companies that had donated to the "Misleading Rx" campaign as of Feb. 29.

Johnson & Johnson New Brunswick, New Jersey $5.86 million
Pfizer New York City $5.86 million
Abbvie Chicago $4.265 million
Amgen Thousand Oaks $4.265 million
Astrazeneca Pharmaceuticals Wilmington, Delaware $4.265 million
Sanofi-Aventis U.S. Bridgewater, New Jersey $4.265 million
Allergan USA Parsippany, New Jersey $2.88 million
Bristol-Myers Squibb New York City $2.88 million
Novartis Pharmaceuticals New York City $2.88 million
Eli Lilly & Co. Indianapolis $2.88 million
Novo Nordisk Plainsboro, New Jersey $2.88 million
Purdue Pharma Stamford, Connecticut $1.105 million
Boehringer Ingelheim Pharmaceuticals Ridgefield, Connecticut $1.105 million
Otsuka America Rockville, Maryland $1.105 million
Genentech South San Francisco $1 million
Mallinckrodt Pharmaceuticals St. Louis $385,000
EMD Serono Rockland, Massachusetts $385,000
Daiichi Sankyo Parsippany, New Jersey $189,732
Biogen Cambridge, Massachusetts $80,000
GlaxoSmithKline Research Triangle, Pennsylvania $80,000
Alkermes Waltham, Massachusetts $52,000
Bayer Whippany, New Jersey $30,000
Astellas Pharma U.S. Northbrook, Illinois $30,000
Celgene Summit, New Jersey $30,000
Takeda Pharmaceuticals U.S.A. Deerfield, Illinois $30,000
Eisai Woodcliff Lake, New Jersey $10,000
Sunovion Pharmaceuticals Marlborough, Massachusetts $10,000
The Medicines Company Parsippany, New Jersey $10,000
Lundbeck Deerfield, Illinois $10,000
Orexigen Therapeutics La Jolla $2,000